Risk and solutions to chimeric antigen receptor-engineered T cell-based cancer immunotherapy
10.16438/j.0513-4870.2015-0977
- VernacularTitle:嵌合抗原受体T细胞肿瘤免疫治疗的风险与对策
- Author:
Miao-miao ZHANG
1
;
Dong-fang JIA
2
;
Yong DIAO
1
Author Information
1. School of Biomedical Science, Institutes of Molecular Medicine, Huaqiao University, Quanzhou 362021, China
2. Quanzhou Medical College, Quanzhou 362021, China
- Publication Type:REVIEWS
- Keywords:
chimeric antigen receptor;
cancer;
immunotherapy;
gene therapy
- From:
Acta Pharmaceutica Sinica
2016;51(7):1032-
- CountryChina
- Language:Chinese
-
Abstract:
The potential of cancer immunotherapy has been demonstrated recently using the chimeric antigen receptors-engineered (CAR) T cells, in which B cell haematological malignancies was successfully treated in clinical trials. However, challenges remain in the translation of the potential benefits into therapy of other types of cancer with similar efficacy and safety. Excessive activation of genetically-modified T cells may cause severe toxicities, such as cytokine storm, on-target toxicities, and tumor lysis syndrome. Genomic integration of viral vectors may cause genetic toxicities due to insertional mutagenesis of important genes. Strategies to overcome these toxicities are proposed and discussed, including the use of suicide genes, combinatorial antigen recognition, on-switch, non-viral vector and other innovative gene therapy strategies, to enhance safety of this promising immunotherapy.
